NEW YORK – The UK's National Institute for Health and Care Excellence on Friday published a draft decision saying that it would recommend osimertinib (AstraZeneca's Tagrisso) for routine use in the National Health Service for first-line treatment of advanced, EGFR mutation-positive non-small-cell lung cancer patients, and second-line treatment of locally advanced or metastatic, EGFR mutation-positive NSCLC patients who have the T790m resistance mutation.